GLIPIZIDE-METFORMIN 2.5-250 MG

What it is

GLIPIZIDE-METFORMIN 2.5-250 MG is how the CMS NADAC file names this product. The FDA NDC Directory lists it as “glipizide and metformin hcl” and “glipizide and metformin hydrochloride”, as its NDCs’ listings variously write the nonproprietary name.

FDA gives its dosage form as tablet, film coated and its route as oral.

FDA lists 4 labelers (the companies named on the label) for its NDCs, among them Teva Pharmaceuticals USA, Inc., Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. and Chartwell RX, LLC.

FDA lists it under 2 Established Pharmacologic Classes: Biguanide and Sulfonylurea.

The NADAC file of 2026-10-14 prices it under 4 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $7.25 for 30 tablets (30 × $0.2418 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

What NADAC measures · Why 30 tablets · NADAC explanation codes

All 4 NDCs

• 00093-7455-01 · Teva Pharmaceuticals USA, Inc. · $0.2418 per EA · eff. 2026-09-23 filed
• 23155-0115-01 · Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. · $0.2418 per EA · eff. 2026-09-23 filed
• 62135-0731-60 · Chartwell RX, LLC · $0.2418 per EA · eff. 2026-09-23 filed
• 68382-0184-01 · Zydus Pharmaceuticals USA Inc. · $0.2418 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

2 other products in the NADAC file share an FDA nonproprietary name with GLIPIZIDE-METFORMIN 2.5-250 MG.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 4 NDCs’ NADAC prices is $0.2418 per EA filed.

Of the 71 other products in FDA’s Biguanide class priced per EA, 60 have a higher middle NADAC price and 11 a lower one. The one in the middle is SYNJARDY XR 5-1,000 MG TABLET, at $5.61111 per EA filed (eff. 2026-09-23).

Of the 20 other products in FDA’s Sulfonylurea class priced per EA, 3 have a higher middle NADAC price and 17 a lower one. The one in the middle is GLIPIZIDE ER 2.5 MG TABLET, at $0.09927 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $8.34 for 30 tablets, at an average of $0.2779 per EA in 2024 (2024-01-01 to 2024-12-31) for “Glipizide-Metformin” and “Glipizide/Metformin HCl”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 224,327 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.